Date: 2017-01-27
Type of information: Nomination
Compound:
Company: Juno Therapeutics (USA - WA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On January 27, 2017, Juno Therapeutics announced the appointment of Corsee D. Sanders as Executive Vice President and Head of Development Operations, effective immediately. She will be responsible for the planning, management, execution, analysis, and reporting of Juno’s clinical trials. Prior to joining Juno, Dr. Sanders was Senior Vice President and Head of Global Clinical Operations and Industry Collaborations at Roche Pharmaceuticals. Prior to her tenure at Roche, which included three years as Head of Global Biometrics and Development Innovation, Dr. Sanders worked in a number of senior leadership roles at Genentech, where her responsibilities included biostatistics, epidemiology, health economics and outcomes research, data management, medical writing, information technology, and biosample management.
Dr. Sanders will report to Mr. Bishop and will be a member of the firm’s Executive Committee. She will lead a newly organized Development Operations group that will combine clinical operations, biometrics and data management, patient operations, medical writing, and program and project management.
Dr. Sanders holds bachelor’s and master’s degrees in statistics from the University of the Philippines, and received a master’s degree and doctorate in statistics from the Wharton School at the University of Pennsylvania.
Financial terms:
Latest news:
Is general: Yes
